Chavaengkiat Suchanant, Suwan Ammarin, Panyakhamlerd Krasean, Wattanachanya Lalita, Bumphenkiatikul Thanapob
Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand.
Division of Gender, Sexual, and Climacteric Medicine, Department of Obstetrics and Gynecology, Chulalongkorn University, Bangkok, Thailand.
Transgend Health. 2024 Dec 16;9(6):501-507. doi: 10.1089/trgh.2023.0056. eCollection 2024 Dec.
Transgender medicine has become rapidly recognized and evolving in the health care system. The consequences of hormone therapy are among the most concerning health issues in the transgender population. This study aims to compare bone turnover markers before and after testosterone administration in hormone-naive transgender men.
This prospective study included 20 hormone-naive transgender men. Comparisons of serum C-terminal cross-linking telopeptide of type I collagen (CTX) at baseline with 12 weeks and 24 weeks were analyzed using Wilcoxon signed-rank test. Serum procollagen type I N-propeptide (P1NP) and osteocalcin levels at 24 weeks compared to baseline were also assessed. Pearson's correlation coefficient analysis was used to compare the correlation between serum bone turnover markers and sex hormone levels.
At 12 weeks after testosterone administration, significant higher serum CTX level compared to baseline (-value 0.035) was demonstrated. At 24 weeks after testosterone administration, there were significant differences in serum CTX, P1NP, and osteocalcin levels compared to baseline (-value 0.019, <0.001, and 0.003, respectively). Serum CTX, P1NP, and osteocalcin levels significantly increased 28.30%, 44.26%, and 21.89%, respectively, at 24 weeks after testosterone treatment. There was a moderate negative correlation between serum CTX and estradiol level.
Testosterone administration in transgender men significantly increased the levels of bone turnover markers. Further, well-controlled studies of bone health in transgender men are required to prove and assess the other aspects of bone status over a long-term follow-up period.Thai Clinical Trial Registry identification number TCTR20220817002.
跨性别医学在医疗保健系统中已迅速得到认可并不断发展。激素治疗的后果是跨性别群体中最令人担忧的健康问题之一。本研究旨在比较初次接受睾酮治疗的跨性别男性在使用睾酮前后的骨转换标志物。
这项前瞻性研究纳入了20名初次接受睾酮治疗的跨性别男性。使用Wilcoxon符号秩检验分析基线时与12周和24周时血清I型胶原C末端交联肽（CTX）的比较情况。还评估了24周时血清I型前胶原N端前肽（P1NP）和骨钙素水平与基线水平的差异。采用Pearson相关系数分析来比较血清骨转换标志物与性激素水平之间的相关性。
在使用睾酮12周后，与基线相比血清CTX水平显著升高（P值为0.035）。在使用睾酮24周后，与基线相比血清CTX、P1NP和骨钙素水平存在显著差异（P值分别为0.019、<0.001和0.003）。在使用睾酮治疗24周时，血清CTX、P1NP和骨钙素水平分别显著升高了28.30%、44.26%和21.89%。血清CTX与雌二醇水平之间存在中度负相关。
跨性别男性使用睾酮显著提高了骨转换标志物水平。此外，需要对跨性别男性的骨骼健康进行严格对照研究，以在长期随访期间证明和评估骨骼状况的其他方面。泰国临床试验注册编号TCTR20220817002。
